Importantly, KEYNOTE-001 and KEYNOTE-010 have shown that patients with advanced NSCLC who demonstrate PD-L1 expression ≥50% are more likely to respond to treatment with the anti- PD-1 immune checkpoint inhibitor pembrolizumab [20,21,22]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.